论文部分内容阅读
目的 评价阿帕替尼联合化疗一线治疗Ⅳ期软组织肉瘤的疗效与安全性.方法 回顾性分析8 例Ⅳ期软组织肉瘤一线接受阿帕替尼联合化疗的患者,每治疗2 个周期后按实体瘤疗效评价标准(RECIST)评价疗效,同时按常见不良反应事件评价标准(CTCAE)评价安全性.结果 所有8 例疗效均可评价,其中无CR病例,PR 1 例,SD 6 例,PD 1 例,患者中位PFS 6 个月,ORR 12.5%,DCR 87.5%,6 个月PFS率50%.Ⅲ-Ⅳ级不良反应中,高血压2 例,手足综合症1 例,骨髓功能抑制1 例,予对照治疗后症状改善.没有不良反应相关的死亡病例.结论 阿帕替尼联合化疗可以抑制软组织肉瘤进展,同时具有较好的安全性,有进一步深入探索的价值.“,”Objective To evaluate the efficacy and safety of apatinib combined with chemotherapy in the first line treatment of stage Ⅳ sarcoma. Methods We retrospectively analyzed 8 cases of stage Ⅳ sarcoma patients who received apatinib combined with chemotherapy as first line therapy. The efficacy was evaluated by RECIST and safety was evaluated by CTCAE every two cycles. Results There were no CR, 1 case was PR, 6 cases were SD and 1 case was PD. The median PFS was 6 months, ORR: 12.5%, DCR: 87.5%, PFS rate was 50% in 6 months. Among the grade Ⅲ-Ⅳ adverse reactions, hypertension was found in 2 cases, hand-foot syndrome in 1 case and bone marrow depression in 1 case. The symptoms were relieved after treatment. There were no deaths associated with adverse reactions. Conclusion Apatinib combined with chemotherapy can inhibit the progression of sarcoma and the combination has good tolerance in patients.